Assignee
VERONA PHARMA PLC
GB·15 granted patents·15 pending applications·105 citations·filing 2004–2025
Top patents by PatentIndex Score
30 records- 0194US12168011B2Formulation production processVERONA PHARMA PLC·Filed 2024·Granted Dec 17, 2024·3 cites·25 claims
- 0292US12251384B1Particulate compositionVERONA PHARMA PLC·Filed 2024·Granted Mar 18, 2025·1 cites·26 claims
- 0392US12194045B1Particulate compositionVERONA PHARMA PLC·Filed 2024·Granted Jan 14, 2025·1 cites·22 claims
- 0490US11759467B2TreatmentVERONA PHARMA PLC·Filed 2020·Granted Sep 19, 2023·4 cites·14 claims
- 0590US10710998B2Compound and processVERONA PHARMA PLC·Filed 2017·Granted Jul 14, 2020·6 cites·31 claims
- 0690US9956171B2Liquid inhalation formulation comprising RPL554VERONA PHARMA PLC·Filed 2015·Granted May 1, 2018·12 cites·18 claims
- 0788US10471063B2Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonistVERONA PHARMA PLC·Filed 2017·Granted Nov 12, 2019·9 cites·10 claims
- 0888US10463665B2Salt of a pyrimido[6,1-A]isoquinolin-4-one compoundVERONA PHARMA PLC·Filed 2016·Granted Nov 5, 2019·9 cites·12 claims
- 0988US9700558B2Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonistVERONA PHARMA PLC·Filed 2014·Granted Jul 11, 2017·12 cites·13 claims
- 1087US10945950B2Liquid inhalation formulation comprising RPL554VERONA PHARMA PLC·Filed 2018·Granted Mar 16, 2021·7 cites·12 claims
- 1187US10864213B2TreatmentVERONA PHARMA PLC·Filed 2015·Granted Dec 15, 2020·6 cites·10 claims
- 1287US7378424B2Derivatives of pyrimido[6, 1-A]isoquinolin-4-oneVERONA PHARMA PLC·Filed 2004·Granted May 27, 2008·19 cites·9 claims
- 1386US11491155B2Salt of a pyrimido[6,1-A]isoquinolin-4-one compoundVERONA PHARMA PLC·Filed 2019·Granted Nov 8, 2022·6 cites·16 claims
- 1486US9717732B2Drug combinationVERONA PHARMA PLC·Filed 2014·Granted Aug 1, 2017·10 cites·11 claims
- 1584US12409180B2Formulation production processVERONA PHARMA PLC·Filed 2024·Granted Sep 9, 2025·0 cites·14 claims
- 1676US2025319090A1Formulation production processVERONA PHARMA PLC·Filed 2025·Application pending·0 cites
- 1774US2024165055A1TreatmentVERONA PHARMA PLC·Filed 2024·Application pending·0 cites
- 1874US2024165054A1TreatmentVERONA PHARMA PLC·Filed 2024·Application pending·0 cites
- 1973US2025049781A1Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalationVERONA PHARMA PLC·Filed 2024·Application pending·0 cites
- 2072US2024173327A1New treatmentVERONA PHARMA PLC·Filed 2024·Application pending·0 cites
- 2167US2024382489A1Liquid pharmaceutical compositionVERONA PHARMA PLC·Filed 2024·Application pending·0 cites
- 2266US2025073240A1New treatmentVERONA PHARMA PLC·Filed 2024·Application pending·0 cites
- 2366US2025170135A1Particulate compositionVERONA PHARMA PLC·Filed 2025·Application pending·0 cites
- 2463US2024165023A1Liquid pharmaceutical compositionVERONA PHARMA PLC·Filed 2024·Application pending·0 cites
- 2553US2023112220A1Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolateVERONA PHARMA PLC·Filed 2021·Application pending·0 cites
- 2651US2021379053A1Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalationVERONA PHARMA PLC·Filed 2019·Application pending·0 cites
- 2751US2022265549A1Pharmaceutical composition comprising ensifentrineVERONA PHARMA PLC·Filed 2020·Application pending·0 cites
- 2846US2025249006A1TreatmentVERONA PHARMA PLC·Filed 2025·Application pending·0 cites
- 2946US2025249008A1Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary diseaseVERONA PHARMA PLC·Filed 2025·Application pending·0 cites
- 3045US2025249007A1Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary diseaseVERONA PHARMA PLC·Filed 2025·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →